IRIS Accounts Production v22.2.0.402 09710681 director 1.8.20 31.7.21 31.7.21 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pure097106812020-07-31097106812021-07-31097106812020-08-012021-07-31097106812019-07-31097106812019-08-012020-07-31097106812020-07-3109710681ns16:EnglandWales2020-08-012021-07-3109710681ns15:PoundSterling2020-08-012021-07-3109710681ns11:Director12020-08-012021-07-3109710681ns11:PrivateLimitedCompanyLtd2020-08-012021-07-3109710681ns11:SmallEntities2020-08-012021-07-3109710681ns11:AuditExempt-NoAccountantsReport2020-08-012021-07-3109710681ns11:SmallCompaniesRegimeForDirectorsReport2020-08-012021-07-3109710681ns11:SmallCompaniesRegimeForAccounts2020-08-012021-07-3109710681ns11:AbridgedAccounts2020-08-012021-07-3109710681ns11:OrdinaryShareClass12020-08-012021-07-3109710681ns11:RegisteredOffice2020-08-012021-07-3109710681ns6:CurrentFinancialInstruments2021-07-3109710681ns6:CurrentFinancialInstruments2020-07-3109710681ns6:ShareCapital2021-07-3109710681ns6:ShareCapital2020-07-3109710681ns6:RetainedEarningsAccumulatedLosses2021-07-3109710681ns6:RetainedEarningsAccumulatedLosses2020-07-3109710681ns11:OrdinaryShareClass12021-07-31
REGISTERED NUMBER: 09710681 (England and Wales)







ABRIDGED UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 JULY 2021

FOR

PRIME PHARM LIMITED

PRIME PHARM LIMITED (REGISTERED NUMBER: 09710681)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2021










Page

Company Information 1

Abridged Balance Sheet 2

Notes to the Financial Statements 3


PRIME PHARM LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 JULY 2021







DIRECTOR: Mr M Mina





REGISTERED OFFICE: Solar House
282 Chase Road
London
N14 6NZ





REGISTERED NUMBER: 09710681 (England and Wales)





ACCOUNTANTS: Freemans Partnership LLP
Chartered Certified Accountants
Solar House
282 Chase Road
London
N14 6NZ

PRIME PHARM LIMITED (REGISTERED NUMBER: 09710681)

ABRIDGED BALANCE SHEET
31 JULY 2021

31.7.21 31.7.20
Notes £    £   
CURRENT ASSETS
Debtors 426,692 459,819
Cash at bank 119 360
426,811 460,179
CREDITORS
Amounts falling due within one year 807,130 860,831
NET CURRENT LIABILITIES (380,319 ) (400,652 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(380,319

)

(400,652

)

CAPITAL AND RESERVES
Called up share capital 4 100 100
Retained earnings (380,419 ) (400,752 )
SHAREHOLDERS' FUNDS (380,319 ) (400,652 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 July 2021.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 July 2021 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

All the members have consented to the preparation of an abridged Statement of Income and Retained Earnings and an abridged Balance Sheet for the year ended 31 July 2021 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 9 September 2022 and were signed by:



Mr M Mina - Director


PRIME PHARM LIMITED (REGISTERED NUMBER: 09710681)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2021


1. STATUTORY INFORMATION

Prime Pharm Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Going Concern
The company shareholders confirm their ability to support Prime Pharm Limited for a period of at least 12 months from the approval of these financial statements.

The shareholders have concluded that the combination of trading forecasts and the long-term support provided by the shareholders, provides reasonable certainty that the Company has adequate working capital and resources to continue in operational existence for the foreseeable future and for those reasons continue to adopt the going concern bases of accounting in preparing these Financial Statements.

Turnover
Turnover represents amounts derived from the sale of goods to customers during the year, and is recognised at the date the risks and rewards of ownership of goods were transferred to the customer. This is stated after trade discounts, other sales taxes and net of VAT.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2020 - 1 ) .

4. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.7.21 31.7.20
value: £    £   
100 Ordinary £1 100 100